Cellular antiviral factors that target particle infectivity of HIV-1

Current HIV Research

Volumn 14, Issue 3, 2016, Pages 211-216

  Goffinet, Christine ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

90K; HIV 1 Nef; IFITM; Interferon; Interferon stimulated genes; Particle infectivity; SERINC

Indexed keywords

ANTIVIRUS AGENT; INTERFERON INDUCED TRANSMEMBRANE PROTEIN; LECTIN GALECTIN SOLUBLE 3 BINDING PROTEIN; NEF PROTEIN; SERINE INCORPORATOR PROTEIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; DIFFERENTIATION ANTIGEN; GLYCOPROTEIN; LEU-13 ANTIGEN; LGALS3BP PROTEIN, HUMAN; MEMBRANE PROTEIN; SERINC1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PROTEIN EXPRESSION; ANIMAL; GENETICS; HIV INFECTIONS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MULTIGENE FAMILY; PHYSIOLOGY; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARRIER PROTEINS; GLYCOPROTEINS; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS; MULTIGENE FAMILY; VIRION; VIRUS ASSEMBLY; VIRUS REPLICATION;

EID: 84961746439     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X14666151216145521     Document Type: Article

References (52)

1. Chertova E, Bess JW, Jr., Crise BJ, et al. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2002; 76(11): 5315-25.
2. Zhu P, Liu J, Bess J, Jr., et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 2006; 441(7095): 847-52.
3. Chojnacki J, Staudt T, Glass B, et al. Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science 2012; 338(6106): 524-8.
4. Lasfar A, Lewis-Antes A, Smirnov SV, et al. Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 2006; 66(8): 4468-77.
5. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFNlambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathogens 2008; 4(3): e1000017.
6. Witte K, Gruetz G, Volk HD, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10(8): 702-14.
7. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J Biol Chem 1993; 268(19): 14245-9.
8. Iacobelli S, Arno E, D'Orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986; 46(6): 3005-10.
9. Linsley PS, Horn D, Marquardt H, et al. Identification of a novel serum protein secreted by lung carcinoma cells. Biochem 1986; 25(10): 2978-86.
10. Ullrich A, Sures I, D'Egidio M, et al. The secreted tumorassociated antigen 90K is a potent immune stimulator. J Biol Chem 1994; 269(28): 18401-7.
11. Rotger M, Dang KK, Fellay J, et al. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. PLoS Pathogens 2010; 6(2): e1000781.
12. Brakebusch C, Sures I, Jallal B, et al. Isolation and functional characterization of the human 90K promoter. Genomics 1999; 57(2): 268-78.
13. Waddell SJ, Popper SJ, Rubins KH, et al. Dissecting interferoninduced transcriptional programs in human peripheral blood cells. PloS One 2010; 5(3): e9753.
14. Lodermeyer V, Suhr K, Schrott N, et al. 90K, an interferonstimulated gene product, reduces the infectivity of HIV-1. Retrovirology 2013; 10: 111.
15. Natoli C, Dianzani F, Mazzotta F, et al. 90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. J Acq Immun Def Synd 1993; 6(4): 370-5.
16. Briggs NC, Natoli C, Tinari N, D'Egidio M, Goedert JJ, Iacobelli S. A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. AIDS Res Hum Retrov 1993; 9(9): 811-6.
17. Longo G, Natoli C, Rafanelli D, et al. Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. Brit J Haematol 1993; 85(1): 207-9.
18. Hyrcza MD, Kovacs C, Loutfy M, et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J Virol 2007; 81(7): 3477-86.
19. Sedaghat AR, German J, Teslovich TM, et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J Virol 2008; 82(4): 1870-83.
20. Klein JS, Bjorkman PJ. Few and far between: how HIV may be evading antibody avidity. PLoS Pathogens 2010; 6(5): e1000908.
21. Sallman AM, Bringeland N, Fredriksson R, Schioth HB. The dispanins: a novel gene family of ancient origin that contains 14 human members. PloS One 2012; 7(2): e31961.
22. Brass AL, Huang IC, Benita Y, et al. The IFITM Proteins Mediate Cellular Resistance to Influenza A H1N1 Virus, West Nile Virus, and Dengue Virus. Cell 2009; 139(7): 1243-54.
23. Wrensch F, Karsten CB, Gnirss K, et al. Interferon-Induced Transmembrane Protein-Mediated Inhibition of Host Cell Entry of Ebolaviruses. J Infect Dis 2015; 212: S210-8.
24. Siegrist F, Ebeling M, Certa U. The small interferon-induced transmembrane genes and proteins. Journal of interferon & cytokine research. Off J Int Soc Interferon Cytokine Res 2011; 31(1): 183-97.
25. Huang IC, Bailey CC, Weyer JL, et al. Distinct patterns of IFITMmediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathogens 2011; 7(1): e1001258.
26. Weidner JM, Jiang D, Pan XB, Chang J, Block TM, Guo JT. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 2010; 84(24): 12646-57.
27. Mudhasani R, Tran JP, Retterer C, et al. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol 2013; 87(15): 8451-64.
28. Anafu AA, Bowen CH, Chin CR, Brass AL, Holm GH. Interferoninducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J Biol Chem 2013; 288(24): 17261-71.
29. Everitt AR, Clare S, Pertel T, et al. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 2012; 484(7395): 519-U146.
30. Schoggins JW, Wilson SJ, Panis M, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011; 472(7344): 481-5.
31. Lu J, Pan QH, Rong LW, Liu SL, Liang C. The IFITM Proteins Inhibit HIV-1 Infection. J Virol 2011; 85(5): 2126-37.
32. Jia R, Pan Q, Ding S, et al. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. J Virol 2012; 86(24): 13697-707.
33. Ding S, Pan Q, Liu SL, Liang C. HIV-1 mutates to evade IFITM1 restriction. Virology 2014; 454-455: 11-24.
34. Jia R, Ding S, Pan Q, Liu SL, Qiao W, Liang C. The C-terminal sequence of IFITM1 regulates its anti-HIV-1 activity. PloS One 2015; 10(3): e0118794.
35. Compton AA, Bruel T, Porrot F, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 2014; 16(6): 736-47.
36. Tartour K, Appourchaux R, Gaillard J, et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. Retrovirology 2014; 11: 103.
37. Li K, Markosyan RM, Zheng YM, et al. IFITM proteins restrict viral membrane hemifusion. PLoS Pathogens 2013; 9(1): e1003124.
38. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathogens 2014; 10(4): e1004048.
39. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 2013; 13(4): 452-64.
40. Deacon NJ, Tsykin A, Solomon A, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270(5238): 988-91.
41. Kestler HW, 3rd, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991; 65(4): 651-62.
42. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. New Eng J Med 1995; 332(4): 228-32.
43. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, Guatelli JC. Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 1994; 68(5): 2906-14.
44. Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB. The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Experiment Med 1994; 179(1): 101-13.
45. Munch J, Rajan D, Schindler M, et al. Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol 2007; 81(24): 13852-64.
46. Carl S, Greenough TC, Krumbiegel M, et al. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J Virol 2001; 75(8): 3657-65.
47. Rosa A, Chande A, Ziglio S, et al. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 2015; 526(7572): 212-7.
48. Usami Y, Wu Y, Gottlinger HG. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 2015; 526(7572): 218-23.
49. Inuzuka M, Hayakawa M, Ingi T. Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. J Biol Chem 2005; 280(42): 35776-83.
50. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993; 67(4): 2182-90.
51. Munch J, Rucker E, Standker L, et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131(6): 1059-71.
52. Rusert P, Fischer M, Joos B, et al. Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. Virology 2004; 326(1): 113-29.